- Education
- Source: Campus Sanofi
- 24 May 2024
InTen Nurse Forum: What is chronic GvHD?
Rezurock▼ (Belumosudil) is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.
The InTen Nurse Forum is a series of promotional meetings for GB HCPs only organised and funded by Sanofi. This Forum provides knowledge in the management of chronic Graft Versus Host Disease (GVHD), as well as an opportunity to hear from your peers on best practices.
What is chronic GvHD?
Length: 20:00
In this video you can learn from John the basics of chronic GvHD, how it impacts quality of life, its classification and measurement, and current treatment challenges.
John Murray is a nurse clinician in BMT at the Haematology and Transplant Unit of The Christie NHSFT where he first joined as the Transplant Coordinator and Apheresis nurse in 2001. Then he developed a new post of nurse clinician in BMT with a special interest in GvHD and late effects of transplant.
He has been Chair of the EBMT UK NAP group and also Chair of the EBMT scientific committee. He became President of EBMT NG in 2017, serving for 4 years and is currently a Past President. He gives regular presentations on issues related to transplantation with a special interest in GvHD. John is also Co-chair of the Equality Diversity and Inclusion committee of EBMT.
More videos in this series
InTen Nurse Forum - ACCEND Framework
More videos in this series
InTen Nurse Forum - ACCEND Framework
Explore more on Campus
Get the latest updates about REZUROCK
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
ROCKstar Study
Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only
Explore more on Campus
Get the latest updates about REZUROCK
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
ROCKstar Study
Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only
MAT-XU-2401966 (v1.0) Date of Preparation: June 2024